Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer
NCT04833205
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Leptomeningeal Metastasis
Lung Cancer
Interventions
DRUG:
Nimotuzumab
Sponsor
Hui Bu